Trials / Completed
CompletedNCT02659020
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 310 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaratumab | Administered IV |
| DRUG | Gemcitabine | Administered IV |
| DRUG | Docetaxel | Administered IV |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2020-07-28
- Completion
- 2021-04-27
- First posted
- 2016-01-20
- Last updated
- 2022-05-09
- Results posted
- 2021-10-11
Locations
48 sites across 10 countries: United States, Australia, France, Germany, Hungary, Israel, Italy, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02659020. Inclusion in this directory is not an endorsement.